Positive results for patients in Patrys’s myeloma trial
15 August, 2013 by Dylan Bushell-EmblingTwo of the six multiple myeloma patients in the second and third cohorts of Patrys’s (ASX:PAB) phase I/IIa trial of PAT-SM6 have shown evidence of stable disease post-dosing.
Dendright and Janssen Biotech to collaborate on rheumatoid arthritis treatment
15 August, 2013Autoimmune therapy business Dendright has signed an agreement with Johnson & Johnson pharmaceutical company Janssen Biotech. The deal is an R&D collaboration and option to license agreement to develop and commercialise Dendright’s tolerising immunotherapy for the treatment of rheumatoid arthritis (RA).
Viralytics to get wider EU oncolytic virus patent
13 August, 2013 by Dylan Bushell-EmblingViralytics (ASX:VLA) will be granted a European patent covering a wider group of oncolytic viruses that bind to ICAM-1, target of the company’s Cavatak candidate.
Compumedics expects return to black for 1H14
13 August, 2013 by Dylan Bushell-EmblingCompumedics (ASX:CMP) expects to report a loss for FY13, but is projecting a return to profitability in 1H14 as it resolves its order-backlog issues.
QIMR changes its name
08 August, 2013In recognition of a large gift from a donor, QIMR will now be known as the QIMR Berghofer Medical Research Institute.
Patrys myeloma trial to move to final group
07 August, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has received safety board approval to move to the final group in its multidose escalation study of PAT-SM6 in multiple myeloma.
TGA miscounted clinical trial numbers
05 August, 2013 by Dylan Bushell-EmblingThe Therapeutic Goods Administration has upwardly revised its statistics on Australian clinical trial notifications from 2009-2012, after discovering errors in its earlier reports.
GTG raising up to $10.6m for BREVAGen expansion
01 August, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) is conducting a capital raising worth up to $10.6m and will use the funds to expand its US market reach for breast cancer risk test BREVAGen.
Chronic inflammatory disease on trial
31 July, 2013 by Susan WilliamsonThe results of clinical trial using cellular therapy in patients with Crohn’s disease were so encouraging the research was published before the trail had been completed.
New WHO centre in Sydney
31 July, 2013A new WHO centre for chronic diseases has been established in Sydney.
Healthcare Management and Leadership unit launched at MGSM
30 July, 2013 by Lauren DavisMacquarie Graduate School of Management (MGSM) has launched a new unit for MBA students, ‘Healthcare Management and Leadership’, which will be offered for the first time in term four 2013 to those that wish to lead, govern or manage within the healthcare sector.
Gtech International to merge with Simavita Holdings
30 July, 2013Gtech International Resources, subsidiary of Genetic Technologies, has moved to acquire Simavita Holdings.
Bionomics begins safety program for cancer antibody
29 July, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has launched IND-enabling pharmacology and toxicology studies for BNC101, its anticancer antibody candidate.
Invion opens phase II trial for chronic bronchitis
26 July, 2013Recruitment has begun for Invion’s phase II trial that aims to repurpose nadolol as a treatment for smoking cessation.
Patrys doses third group in multiple myeloma trial
24 July, 2013Patrys (ASX:PAB) has completed initial treatment for the third of four groups of patients in a phase I/IIa trial of the company’s anticancer antibody, PAT-SM6, in multiple myeloma.
